title: The effect of sacral neuromodulation on anticholinergic use and expenditures in a privately insured population.
abstract: OBJECTIVE
  Sacral neuromodulation is Food and Drug Administration approved for many types of voiding dysfunction. Goals of treatment often include cessation of anticholinergic therapy. With the goal of understanding the impact of sacral neuromodulation on anticholinergic use, we analyzed patterns of care using a national claims-based dataset.
  
  
  METHODS
  The Ingenix (i3) data base contains insurance claims, including utilization and cost data, for 75 large employers. De-identified patients who underwent sacral neuromodulation between 2002 and 2007 were identified by the unique current procedural terminology-4 procedure code for pulse generator implantation, code 64590. The number and costs of anticholinergic prescriptions were compared before and after treatment.
  
  
  RESULTS
  There were 266 percutaneous and 794 two-staged procedures performed from 2002 to 2007 in the i3 dataset. A total of 484 pulse generator implantations were performed, representing 46% of the test procedures. During the year prior to pulse generator placement, each patient purchased an average of 2.1 prescriptions for an anticholinergic agent (SD 3.5). During the year after neuromodulation, each patient purchased an average of 1.0 prescription (SD 2.3, p < 0.0001 by t-test). Prescription charges were $241.31 per patient before and $103.52 after neuromodulation, a statistically significant cost difference (p < 0.0001 by t-test). During the year before the procedure, 50% of patients filled anticholinergic prescriptions. This decreased to 23% after the procedure (p < 0.0001 by chi-square test).
  
  
  CONCLUSIONS
  Sacral neuromodulation was associated with a significant decrease in the use of anticholinergic medication. Cost-effectiveness analyses that take into account patient quality-adjusted life years are needed to determine the true cost-benefit ratio of sacral neuromodulation.
authors: Department of Urology, UCLA, Los Angeles, CA, USA; Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
authors: Jennifer T
authors: JT
authors: Anger
authors: Anne P
authors: AP
authors: Cameron
authors: Rodger
authors: R
authors: Madison
authors: Christopher S
authors: CS
authors: Saigal
authors: J Quentin
authors: JQ
authors: Clemens
mesh_terms: D018680:Cholinergic Antagonists / Q000191:economics / Q000627:therapeutic use*; D016208:Databases, Factual; D004363:Drug Utilization; D006264:Health Benefit Plans, Employee / Q000706:statistics & numerical data; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000706:statistics & numerical data*; D008160:Lumbosacral Plexus / Q000503:physiopathology; D011306:Prescription Fees / Q000706:statistics & numerical data*; D055656:Prescriptions / Q000706:statistics & numerical data*; D062187:Spinal Cord Stimulation / Q000191:economics; D014481:United States; D014555:Urination Disorders / Q000191:economics / Q000628:therapy
chemical_list: D018680:Cholinergic Antagonists
keywords: Claims data; Ingenix (i3); cost; overactive bladder
references: Urology. 2007 Dec;70(6):1069-73; discussion 1073-4
references: 18158016
references: J Urol. 2011 Mar;185(3):970-5
references: 21247596
references: Neurourol Urodyn. 2010;29 Suppl 1:S18-23
references: 20419795
references: BJU Int. 2011 Aug;108(4):558-64
references: 21166750
references: Urology. 2010 Oct;76(4):835-40
references: 20430422
references: J Urol. 2009 Dec;182(6):2799-804
references: 19837427